Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Lo, Aminata C ^a   Faye, Babacar ^a   Ba, El Hadj ^c   Cisse, Badara ^a,b   Tine, Roger ^a   Abiola, Annie ^a   Ndiaye, Magatte ^a   Ndiaye, Jean L A ^a   Ndiaye, Daouda ^a   Sokhna, Cheikh ^c   Gomis, Jules F ^a   Dieng, Yemou ^a   Faye, Omar ^a   Ndir, Omar ^a   Milligan, Paul ^b   Cairns, Matthew ^b   Hallett, Rachel ^b   Sutherland, Colin ^b   Gaye, Oumar ^a  

^a UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

Author keywords

Amodiaquine; Pfcrt; Pfdhfr; Pfdhps; Pfmdr1; Plasmodium falciparum; Prevalence; SMC; Sulphadoxine pyrimethamine

Indexed keywords

AMODIAQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; MOLECULAR MARKER; MULTIDRUG RESISTANCE PROTEIN 1; PLASMODIUM FALCIPARUM CHLOROQUINE TRANSPORTER; PLASMODIUM FALCIPARUM MULTIDRUG RESISTANCE 1; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CODON; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL MALARIA CHEMOPREVENTION;

AMODIAQUINE; ANTIMALARIALS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENETIC MARKERS; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MUTATION RATE; PLASMODIUM FALCIPARUM; PREVALENCE; PYRIMETHAMINE; SENEGAL; SULFADOXINE;

EID: 84876728255     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-137     Document Type: Article

References (32)

1. WHO, World Malaria Report 2011 NLM Classification WC 765 Global Malaria Programme ISBN 978 92 4 156440 3 2011
2. WHO Policy recommandation, Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-regions in Africa WHO Global Malaria Programme 2012
3. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, J Infect Dis 2002 185 380 388 10.1086/338566 11807721
4. Folate antagonists and mechanisms of resistance. Plowe C, Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery Totowa, New Jersey: Humana Press, Rosenthal PJ, 2001 173 190
5. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo C, Björkman A, Infect Genet Evol 2006 6 309 314 10.1016/j.meegid.2005.09.001 16271310
6. In vitro amodiaquine resistance and its association with mutation in pfcrt and pfmdr1 genes of P. falciparum isolates from Nigeria. Folarin OA, Bustamante C, Gbotosho GO, Sowunmi A, Zalis MG, Oduala AMJ, Happi CT, Acta Trop 2011 120 224 230 10.1016/j.actatropica.2011.08.013 21920347
7. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Faye B, Ndiaye M, Ndiaye JL, Annie A, Tine RC, Lo AC, Ndiaye M, Sow D, De Sousa A, Gaye O, Parasitol Res 2011 109 133 138 10.1007/s00436-010-2236-9 21207062
8. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, Santara G, Diawara H, Conare T, Djimde A, Chandramohan D, Cousens S, Milligan PJ, Diallo DA, Doumbo OK, Greenwood B, PLoS Med 2011 8 1000407 10.1371/journal.pmed.1000407 21304923
9. A molecular marker for chloroquine-resistant falciparum malaria. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, N Engl J Med 2001 344 257 263 10.1056/NEJM200101253440403 11172152
10. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Cisse B, Sokhna C, Boulanger D, Milet J, Ba el H, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trape JF, Lancet 2006 367 659 667 10.1016/S0140-6736(06)68264-0 16503464
11. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, Am J Trop Med Hyg 1995 52 565 568 7611566
12. Dynamics of pfcrt alleles CVMNK and CVIET in chloroquine-treated Sudanese patients infected with Plasmodium falciparum. Gadalla NB, Elzaki SE, Mukhtar E, Warhurst DC, El-Sayed B, Sutherland CJ, Malar J 2010 9 74 10.1186/1475-2875-9- 74 20226032
13. Novel pfdhps haplotypes among imported cases of Plasmodium falciparum malaria in the United Kingdom. Sutherland CJ, Fifer H, Pearce RJ, bin Reza F, Nicholas M, Haustein T, Njimgye-Tekumafor NE, Doherty JF, Gothard P, Polley SD, Chiodini PL, Antimicrob Agents Chemother 2009 53 3405 3410 10.1128/AAC.00024-09 19433569
14. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. Aubouy A, Jafari S, Huart V, Migot-Nabias F, Mayombo J, Durand R, Bakary M, Le Bras J, Deloron P, J Antimicrob Chemother 2003 52 43 49 10.1093/jac/dkg294 12805261
15. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Faye B, Ndiaye JL, Ndiaye D, Dieng Y, Faye O, Gaye O, Malar J 2007 6 80 10.1186/1475-2875-6-80 17570848
16. Evaluation de la chimiorésistance à la sulfadoxine- pyrimethamine et des mutations des genes dhfr et dhps dans le district de sante de Ndu au nord-ouest Cameroun. Nfor ENMW, Njifutri N, Mbulli IA, Tawé B, Masumbi NP, Venyoka A, Afr J Sci Tech 2007 8 52 55
17. Field-based evidence for linkage of mutations associated with chloroquine (pfcrt/pfmdr1) and sulfadoxine-pyrimethamine (pfdhfr/pfdhps) resistance and for the fitness cost of multiple mutations in P. falciparum. Osman ME, Mockenhaupt FP, Bienzle U, Elbashir MI, Giha HA, Infect Genet Evol 2007 7 52 59 10.1016/j.meegid.2006.03.008 16690361
18. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, Dao LD, Mshinda H, Tanner M, Watkins WM, Simps PF, Hyde JE, Mol Biochem Parasitol 1997 89 161 177 10.1016/S0166-6851(97)00114-X 9364963
19. In vitro activities of piperaquine, lumefantrine and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A, Antimicrob Agents Chemother 2009 53 5069 5073 10.1128/AAC.00638-09 19770282
20. Mutations in PFCRT K76T do not correlate with sulfadoxine-pyrimethamine- amodiaquine failure in Pikine, Senegal. Sarr O, Ahouidi AD, Ly O, Daily JP, Ndiaye D, Ndir O, Mboup S, Wirth DF, Parasitol Res 2008 103 765 769 10.1007/s00436-008-1038-9 18523801
21. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV, J Infect Dis 2003 187 1870 1875 10.1086/375419 12792863
22. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Bjorkman A, Am J Trop Med Hyg 2003 68 413 415 12875289
23. Prevalence of pfmdr1, pfcrt, pfdhfr and pfdhps mutations associated with drug resistance, in Luanda, Angola. Figueiredo P, Benchimol C, Lopes D, Bernardino L, do Rosario VE, Varandas L, Nogueira F, Malar J 2008 7 236 10.1186/1475-2875-7-236 19014684
24. Plasmodium falciparum pfcrt and pfmdr1 polymorphisms are associated with the pfdhfr N108 pyrimethamine-resistance mutation in isolates from Ghana. Mockenhaupt FP, Eggelte TA, Till H, Bienzle U, Trop Med Int Health 2001 6 749 755 10.1046/j.1365-3156.2001.00792.x 11679121
25. Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86. Mockenhaupt FP, Ehrhardt S, Eggelte TA, Agana-Nsiire P, Stollberg K, Mathieu A, Markert M, Otchwemah RN, Bienzle U, Ann Trop Med Parasitol 2005 99 723 732 10.1179/136485905X75395 16297285
26. Artemisinin-based combination therapy for treating uncomplicated malaria. Sinclair DZB, Donegan S, Olliaro P, Garner P, Cochrane Database Syst Rev 2009 3 D007483 19588433
27. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine- pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Some AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouedraogo JB, Rosenthal PJ, Antimicrob Agents Chemother 2010 54 1949 1954 10.1128/AAC.01413-09 20231394
28. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. Tagbor H, Bruce J, Browne E, Randal A, Greenwood B, Chandramohan D, Lancet 2006 368 1349 1356 10.1016/S0140-6736(06)69559-7 17046467
29. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, Meshnick SR, Mugittu K, Naidoo I, Price RN, Shafer RW, Sibley CH, Sutherland CJ, Zimmerman PA, Rosenthal PJ, Malar J 2007 6 121 10.1186/1475-2875-6-121 17822535
30. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, Carneiro I, Newman RD, Grobusch MP, Greenwood B, Chandramohan D, Gosling RD, PLoS One 2010 5 12618 10.1371/journal.pone.0012618 20838642
31. Using rapid diagnostic tests as source of malaria parasite DNA for molecular analyses in the era of declining malaria prevalence. Ishengoma DS, Lwitiho S, Madebe RA, Nyagonde Nyagonde N, Ola Persson O, Vestergaard LS, Bygbjerg IC, Lemnge MM, Alifrangis M, Malar J 2011 10 6 10.1186/1475-2875-10-6 21226910
32. Rapid diagnostic tests as a source of DNA for Plasmodium species-specific real-time PCR. Cnops L, Boderie M, Gillet P, Van Esbroeck M, Jacobs J, Malar J 2011 10 67 10.1186/1475-2875-10-67 21435256